Today: 1 July 2026
Browse Category

NASDAQ:MGTX 10 November 2025 - 17 May 2026

MeiraGTx Falls 5.5% as MGTX Shares Slip, Investors Keep Watch Next Week

MeiraGTx Falls 5.5% as MGTX Shares Slip, Investors Keep Watch Next Week

MeiraGTx Holdings plc is under pressure early this week after a late Friday slide knocked back most of its recent gains from pipeline news and funding headlines. The stock closed at $9.40 on Friday, down 5.5% for the day and 4.3% over the last five sessions, market data shows. MeiraGTx is moving from a research-focused story to one centered around regulatory filings. Last week, the company posted first-quarter results, said it received FDA Breakthrough Therapy Designation for AAV2-hAQP1, which could speed talks with regulators on key drugs for hard-to-treat diseases, and said it's advancing bota-vec toward filings in the U.S., Europe, the U.K., and Japan.
17 May 2026
··
Eli Lilly (LLY) Pops on Fresh Deal Spree: MeiraGTx Gene Therapy Tie‑Up, New AI Collaboration, and Leerink Upgrade — Nov. 10, 2025

Eli Lilly (LLY) Pops on Fresh Deal Spree: MeiraGTx Gene Therapy Tie‑Up, New AI Collaboration, and Leerink Upgrade — Nov. 10, 2025

Eli Lilly and Company opened the week with a burst of dealmaking and Wall Street momentum. The pharma giant announced a rights deal for a pediatric blindness gene therapy from MeiraGTx, unveiled a new AI‑driven discovery partnership, and captured an analyst upgrade with a higher price target—moves that had LLY trading sharply higher intraday. Reuters+2 The MeiraGTx alliance hands Lilly a potential first‑in‑class therapy for LCA4 that, in a small study, has shown the ability to restore visual function in children born legally blind. Beyond the single asset, Lilly secures platform access—vector and riboswitch technologies—that could seed a broader ophthalmology pipeline. Strategically, this builds on Lilly’s Adverum acquisition in October for an intravitreal wet AMD gene therapy candidate, signaling a deliberate expansion into vision care alongside its metabolic crown jewels. BioPharma Dive+2Reuters+2
10 November 2025
······

Stock Market Today

  • KPIT Technologies sinks 15% after dim FY27 view, JPMorgan cuts to Underweight
    July 1, 2026, 2:33 AM EDT. KPIT Technologies shares tumbled more than 15% and hit their lower circuit after the company warned on Q1 FY27 profits. KPIT said Q2 revenue will likely stay flat. JPMorgan lowered its rating to 'Underweight' from 'Neutral' and slashed the target price to Rs 550 from Rs 700. The firm pointed to weaker spending from European auto makers, highlighting cuts at BMW and Volkswagen, and warned KPIT's revenue could drop for a second year. JP Morgan flagged pressure on EBITDA and net margins, with little room for cost cuts in the near term. KPIT stock is down 54% this year, far behind the Nifty 50.
Go toTop